These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Lee TW; Fedorak RN Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917 [TBL] [Abstract][Full Text] [Related]
5. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience. Shen H; Lipka S; Katz S J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182 [No Abstract] [Full Text] [Related]
6. Mucosal healing and anti TNFs in IBD. van Assche G; Vermeire S; Rutgeerts P Curr Drug Targets; 2010 Feb; 11(2):227-33. PubMed ID: 20210770 [TBL] [Abstract][Full Text] [Related]
7. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978 [TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Gisbert JP; Marín AC; McNicholl AG; Chaparro M Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884 [TBL] [Abstract][Full Text] [Related]
9. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease. Smith LS; Nelson M; Dolder CR Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143 [TBL] [Abstract][Full Text] [Related]
10. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment]. Schreiber S Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889 [TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Mitoma H; Horiuchi T; Tsukamoto H; Ueda N Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553 [TBL] [Abstract][Full Text] [Related]
12. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Peyrin-Biroulet L Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259 [TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564 [TBL] [Abstract][Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Williams CJ; Peyrin-Biroulet L; Ford AC Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171 [TBL] [Abstract][Full Text] [Related]
16. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. Bourne T; Fossati G; Nesbitt A BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114 [TBL] [Abstract][Full Text] [Related]
17. [Treatment with anti-TNFalpha agents in Crohn's disease: what drug we have to use and when?]. Gomollón F; López SG Acta Gastroenterol Latinoam; 2008 Jun; 38(2):133-45. PubMed ID: 18697408 [TBL] [Abstract][Full Text] [Related]
18. [Main therapeutic advances in IBD in 2007]. Felley C; Mottet C; Maillard MH; Hess J; Delarive J; Michetti P Rev Med Suisse; 2008 Jan; 4(141):200, 202-4, 206-8 passim. PubMed ID: 18335885 [TBL] [Abstract][Full Text] [Related]
19. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Chang JT; Lichtenstein GR Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964 [TBL] [Abstract][Full Text] [Related]
20. Crohn's targeted therapy: myth or real goal? Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]